Literature DB >> 7654733

Paramyxovirus infection in lung transplant recipients.

C H Wendt1, J M Fox, M I Hertz.   

Abstract

BACKGROUND: Respiratory infections are common after lung transplantation. The significance of respiratory paramyxoviruses, respiratory syncytial virus, and parainfluenza virus in lung transplant recipients has not been determined.
METHODS: In a retrospective fashion, we examined the incidence and clinical characteristics of paramyxovirus infection in 84 consecutive lung transplant recipients at the University of Minnesota Hospital and Clinics from 1986 through 1993.
RESULTS: We identified 19 cases of paramyxovirus infection in 18 patients (21% of all transplant recipients). All patients had symptoms with lower respiratory tract involvement, and nine (47%) had coexisting upper respiratory involvement. Symptom onset was 24 to 2056 days after transplantation (median = 260 days). Respiratory syncytial virus infection was seasonal (January through June), but parainfluenza virus infection occurred throughout the year. Six patients showed a decline in spirometry (26% +/- 2.8% decrease in forced expiratory volume in 1 second); four returned to baseline. Diagnosis was made by bronchoalveolar lavage in 15 cases, nasopharyngeal swab in three cases, and sputum in one case. Most patients (74%) were treated with ribavirin, and all but one treated patient recovered fully. In untreated patients, respiratory syncytial virus contributed to one death and one parainfluenza virus infection resulted in a persistent reduction in spirometry. Age was the strongest predictor of infection, with a higher incidence in patients under 18 years old (57%, p < 0.05). Preexisting obliterative bronchiolitis did not correlate with an increased incidence of paramyxovirus infection (20% with obliterative bronchiolitis, 22% without obliterative bronchiolitis; p > 0.05).
CONCLUSIONS: Lower respiratory tract infection with paramyxovirus is common in lung transplant recipients and capable of causing death or a permanent reduction in pulmonary function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654733

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  22 in total

1.  Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation.

Authors:  Lewis H McCurdy; Barney S Graham
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 2.  Nosocomial spread of viral disease.

Authors:  C Aitken; D J Jeffries
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

Review 3.  Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.

Authors:  S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

4.  Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997.

Authors:  H Laurichesse; D Dedman; J M Watson; M C Zambon
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

5.  Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro.

Authors:  T L Gower; B S Graham
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation.

Authors:  Kari Neemann; Alison Freifeld
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

7.  Absence of evidence that respiratory viral infections influence pediatric lung transplantation outcomes: Results of the CTOTC-03 study.

Authors:  Stuart C Sweet; Hyunsook Chin; Carol Conrad; Don Hayes; Peter S Heeger; Albert Faro; Samuel Goldfarb; Ernestina Melicoff-Portillo; Thalachallour Mohanakumar; Jonah Odim; Marc Schecter; Gregory A Storch; Gary Visner; Nikki M Williams; Karen Kesler; Lara Danziger-Isakov
Journal:  Am J Transplant       Date:  2019-07-25       Impact factor: 8.086

Review 8.  Respiratory viruses other than influenza virus: impact and therapeutic advances.

Authors:  W Garrett Nichols; Angela J Peck Campbell; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

9.  Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury.

Authors:  Katrina Bazemore; Michael Rohly; Nitipong Permpalung; Kai Yu; Irina Timofte; A Whitney Brown; Jonathan Orens; Aldo Iacono; Steven D Nathan; Robin K Avery; Hannah Valantine; Sean Agbor-Enoh; Pali D Shah
Journal:  J Heart Lung Transplant       Date:  2021-05-30       Impact factor: 10.247

10.  Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies.

Authors:  Auke de Zwart; Annelies Riezebos-Brilman; Gerton Lunter; Judith Vonk; Allan R Glanville; Jens Gottlieb; Nitipong Permpalung; Huib Kerstjens; Jan-Willem Alffenaar; Erik Verschuuren
Journal:  Clin Infect Dis       Date:  2022-07-06       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.